Internal Medicine, Medical Oncology · Hackensack, NJ
NPI
1295994614
Since 2008
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
92 2nd St
Hackensack, NJ, 07601
Phone (551) 996-3925
Groups this clinician bills Medicare through
Medicare paid, 2024
$321K
11,079 services
Medicare patients, 2024
344
Average age 75
Drug cost, 2024
$3.7M
746 prescriptions
Company payments, 2025
$512K
From 27 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jamie L Koprivnikar was code J0885 (injection, epoetin alfa, (for non-esrd use), 1000 units), 5,980 times for 27 patients. In total Jamie L Koprivnikar billed 11,079 services in 28 codes, and Medicare paid $321K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-01-26.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 5,980 | 27 | $6.40 | $38K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,310 | 271 | $13.92 | $18K |
| 99214 Office E&M - Established | Office | 709 | 227 | $107.02 | $76K |
| 99213 Office E&M - Established | Office | 576 | 174 | $76.79 | $44K |
| 99215 Office E&M - Established | Office | 448 | 165 | $151.87 | $68K |
| 99233 Hospital E&M - Subsequent | Facility | 363 | 49 | $99.57 | $36K |
| 96372 Injection Administration | Office | 129 | 29 | $11.92 | $1,538 |
| 99223 Hospital E&M - Initial | Facility | 56 | 40 | $146.01 | $8,176 |
| 38221 Other Organ Systems | Office | 53 | 44 | $142.01 | $7,527 |
| 38220 Other Organ Systems | Office | 53 | 44 | $70.05 | $3,713 |
| 85097 Test - Miscellaneous | Office | 42 | 36 | $60.59 | $2,545 |
| 99238 Hospital Discharge Management | Facility | 35 | 26 | $68.93 | $2,412 |
| 99232 Hospital E&M - Subsequent | Facility | 24 | 11 | $66.51 | $1,596 |
| 99205 Office E&M - New | Office | 18 | 18 | $190.89 | $3,436 |
| 99239 Hospital Discharge Management | Facility | 13 | 11 | $89.78 | $1,167 |
By year: 2022 $331K for 12,753 services; 2023 $329K for 15,192 services; 2024 $321K for 11,079 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,015 | 267 | $7.50 | $7,611 |
| 85027 Blood Count | 212 | 89 | $6.33 | $1,342 |
Medicare prescription drug claims, 2024
In 2024, the drug Jamie L Koprivnikar prescribed most often to Medicare patients was Jakafi (Ruxolitinib Phosphate), with 71 prescriptions and refills. In total Jamie L Koprivnikar wrote 746 Medicare prescriptions that cost $3.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Jakafi Ruxolitinib Phosphate | 71 | 71 | 16 | $1.1M |
| Acyclovir Generic | 52 | 64 | 19 | $601 |
| Hydroxyurea Generic | 50 | 87 | 20 | $1,245 |
| Ciprofloxacin Hcl Generic | 47 | 47 | 15 | $1,228 |
| Imatinib Mesylate Generic | 43 | 43 | Under 11 | $65K |
| Venclexta Venetoclax | 38 | 38 | 15 | $105K |
| Fluconazole Generic | 35 | 35 | Under 11 | $3,291 |
| Posaconazole Generic | 32 | 32 | 14 | $35K |
| Ondansetron Hcl Generic | 21 | 21 | Under 11 | $85.82 |
| Deferasirox Generic | 20 | 20 | Under 11 | $48K |
| Cyclosporine Modified Cyclosporine, Modified | 17 | 20 | Under 11 | $1,762 |
| Vonjo Pacritinib Citrate | 17 | 17 | Under 11 | $433K |
| Inqovi Decitabine/Cedazuridine | 16 | 16 | Under 11 | $132K |
| Enoxaparin Sodium Generic | 14 | 16 | Under 11 | $3,776 |
| Onureg Azacitidine | 13 | 13 | Under 11 | $328K |
Brand drugs: 255 claims; generic drugs: 491 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jamie L Koprivnikar $512K ($512K in general payments such as food, travel and fees) from 27 companies. The largest payer was Sobi, Inc with $95K.
| Company | Payments | Amount |
|---|---|---|
| Sobi, Inc SOBI.ST | 47 | $95K |
| Syndax Pharmaceuticals, Inc. SNDX | 50 | $76K |
| Alexion Pharmaceuticals, Inc. AZN | 39 | $64K |
| Geron Corporation GERN | 38 | $54K |
| E.R. Squibb & Sons, L.L.C. BMY | 30 | $53K |
| Astellas Pharma US Inc 4503.T | 27 | $36K |
| Servier Pharmaceuticals LLC | 23 | $32K |
| Genzyme Corporation SNY | 19 | $27K |
| Novartis Pharmaceuticals Corporation NVS | 13 | $23K |
| Amgen Inc. AMGN | 13 | $19K |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.